Back
BridgeBio Pharma, Inc. (BBIO)
BiotechnologyBBIO · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$85.89
−4.73%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-3.79
ROE
Gross margin
95.1%
Debt/Equity
Revenue growth
66.8%
P/B ratio
Beta
Forward P/E
BridgeBio Pharma, Inc. — company intelligence
Earnings surprises
Q1 2026$-0.84 vs $-0.69 est-21.4%
Q4 2025$-1.00 vs $-0.76 est-32.1%
Q3 2025$-0.95 vs $-0.91 est-4.8%
Q2 2025$-0.95 vs $-0.86 est-10.4%
Insider activity · 90 days
24 buys38 sellsnet -166,024 shares
Cook Jennifer E.Sell 37,167 · Jun 24, 2026
Cook Jennifer E.other 17,167 · Jun 24, 2026
Cook Jennifer E.other 20,000 · Jun 24, 2026
Recent SEC filings
8-K — Material event reportJul 2, 2026
8-K — Material event reportJun 26, 2026
4 — Insider transaction reportJun 24, 2026
Latest news
BridgeBio Pharma Agrees To Sell Up To $1B Of Convertible Preferred Stock To Sixth Street And KKR's HealthCare Royalty — Benzinga · 1w ago
ValuEngine Weekly Market Summary And Commentary — SeekingAlpha · 1w ago
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish — SeekingAlpha · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About BridgeBio Pharma, Inc.
Weekly undervalued picks (like BBIO)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.